Group 1 - The core theme of the "Beijing Public Fund High-Quality Development Series Activities" is "New Era, New Fund, New Value," focusing on investor education, service to the real economy, and industry structural transformation [1] - The public fund industry in Beijing is a key player in China's capital market, with a concentration of financial institutions that support high-quality development [1] - The China Securities Regulatory Commission (CSRC) released an action plan in May 2025 to promote high-quality development of public funds, emphasizing investor interests and enhancing research and service capabilities [1] Group 2 - Harvest Fund, one of the earliest fund companies in China, emphasizes fundamental investment driven by in-depth research and has made significant contributions in key areas related to the "Five Major Articles" [2] - As of June 30, 2025, Harvest Fund has distributed over 112.8 billion yuan in dividends to its investors and has actively reduced management fees for several products [2] - The essence of asset management is service, with public funds evolving from mere product sellers to comprehensive wealth solution providers [2] Group 3 - Harvest Fund has systematically developed its ETF product line in response to industrial upgrades, covering the entire chain in the digital economy and creating a complete ecosystem in the new energy sector [3] - Public funds are now seen as important financial intermediaries that connect the real economy with capital resources and facilitate the implementation of national strategies [3] - Harvest Fund aims to continue serving the real economy and deepen its research system reform while enhancing responsible investment awareness [3]

Core Viewpoint - The Chinese financial industry in 2018 is characterized by a focus on regulatory strengthening, risk prevention, and high-quality development, with the implementation of the "Asset Management New Regulations" driving a shift from scale-oriented growth to quality-oriented growth [1] Group 1: Development of WISE Platform - The WISE platform was developed from scratch by Western Li De Fund, marking a significant shift in the public fund industry towards self-built investment research systems [1] - Over six years, the WISE platform has evolved from focusing on process standardization to data visualization and analysis, and now towards intelligent capabilities [1] - WISE has become a distinctive feature of Western Li De Fund, aiding investment decision-making and gaining recognition from peers and regulators [1] Group 2: Cultural Foundations - The establishment of a "transparent" investment research culture is a cornerstone of Western Li De Fund's development, emphasizing strategy transparency, decision transparency, and evaluation transparency [5][6] - The transparent culture has attracted talented individuals who are passionate about investment research, fostering a cohesive team environment [7] - The integration of investment and research teams is facilitated by a matrix structure, enhancing collaboration and resource sharing [7] Group 3: Challenges and Achievements - The development of the WISE system faced significant external financial pressures and internal personnel challenges, requiring deep involvement from business staff [9][10] - By 2021, the framework of the WISE system was largely established, improving cross-departmental collaboration and creating a systematic approach to investment research [11] - The WISE system is designed to support investment decisions based on the investment manager's knowledge and experience, while also providing a robust framework for decision-making [11] Group 4: Future Aspirations - The goal of the WISE system is to transform effective investment philosophies into replicable algorithms, ensuring long-term value creation for investors [12][13] - The vision includes building a "century-old store" in the asset management industry, with the WISE system serving as a foundational tool for achieving this ambition [13]

Core Points - The Gansu Provincial Government awarded the Provincial Governor's Financial Award for 2023-2024 to units that made significant contributions to the economic and social development of Gansu Province, with the Industrial and Commercial Bank of China (ICBC) Gansu Branch receiving the award for the eighth consecutive year [1] - ICBC Gansu Branch has actively integrated into Gansu's "Four Strong" action development layout, contributing positively to the province's economic and social development [1] Financial Performance - In 2024, ICBC Gansu Branch is implementing the "Five Major Articles" strategy, focusing on technological finance to support the transformation of traditional industries and the development of innovative industries [1] - The bank reported net increases in specialized, refined, and new technology loans of 1.39 billion, 2.53 billion, and 5.76 billion respectively compared to the beginning of the year [1] - Green finance initiatives led to a net increase of 3.63 billion in green finance loans [1] Customer Service and Outreach - The bank has expanded its outreach in inclusive finance, adding 2,818 new inclusive customers year-on-year [1] - In the area of pension finance, the bank strengthened its mechanism, with pension custody scale increasing by 2.73 billion compared to the beginning of the year, maintaining the leading position in the Gansu market for legal custody and account management [1] Digital Transformation - ICBC Gansu Branch is advancing its digital finance initiatives by enhancing data empowerment and integrating internal and external data systems, as well as building a network security protection system [1]

科技金融方面，嘉实基金持续加强专业投研能力建设，尤其聚焦以新质生产力为代表的新生产力与生产 关系的研究，紧抓新一轮科技革命带来的历史机遇，发挥在科技投资方面的积淀和优势，为客户在值得 聚焦的方向上前瞻布局，力争创造长期可持续回报。 绿色金融方面，嘉实基金坚持积极探索实践，除了在投资研究中重点关注绿色低碳相关股债资产，还致 力于立足绿色金融体系持续发展，将战略规划、制度建设、风险治理、长期收益考量等纳入系统性研究 和投资实践。 普惠金融方面，嘉实基金始终坚持以投资者为本，着力打造"客需解构—策略形成—产品供给—投研匹 配—品质管理"互为一体的客需驱动体系，从客户需求和风险收益特征出发，不断优化产品供给和客户 需求的针对性、策略化与工具性匹配。围绕投资者获得感提升，嘉实还构建了专业化、精准化、敏捷化 的服务体系。 中证报中证网讯（记者 张凌之）近日，在北京证监局指导下，北京证券业协会携手北京公募基金管理 人、基金销售机构、基金评价机构及多家主流媒体，共同启动"新时代·新基金·新价值——北京公募基金 高质量发展在行动"活动。据了解，北京地区各基金公司积极参与，纷纷通过线上、线下各类主题活 动，汇聚合力，助力行业高质 ...

Core Viewpoint - Huajian Medical (01931) has announced a strategic partnership with Renhe Pharmaceutical (000650.SZ) to establish the world's first vertical RWA exchange focused on the OTC sector in the United States, marking a significant step in the implementation of its "ETHK blockchain financial ecosystem strategy" [1][2] Group 1: Strategic Collaboration - The collaboration with Renhe Pharmaceutical signifies a new phase in the large-scale implementation and value realization of the "ETHK" blockchain financial ecosystem strategy [1] - This partnership serves as a benchmark case for the innovative "ETHK global RWA exchange" business model, aiming to create a replicable model that validates the feasibility and potential of this innovation [1] Group 2: Vision and Mission - The company believes that the ultimate mission of financial technology is to serve the real economy and create inclusive value, which this collaboration exemplifies [2] - The goal is to empower classic national brands like Renhe Pharmaceutical to achieve digital transformation and promote successful ecological models across various industries, contributing to national industrial upgrades and the development of the digital economy [2] Group 3: Future Outlook - The board is confident that this strong alliance will generate significant synergies, positively impacting the strategic transformation and value reassessment of both companies [2] - The company aims to ensure the successful launch and stable operation of the world's first OTC RWA exchange through close collaboration with Renhe Pharmaceutical, leveraging both parties' resources [2]

Core Viewpoint - The strategic partnership between Huajian Medical and Renhe Pharmaceutical aims to establish the world's first vertical RWA exchange focused on the OTC sector in the United States, marking a significant step in Huajian's ETHK blockchain financial ecosystem strategy [1][2] Group 1: Strategic Collaboration - The collaboration with Renhe Pharmaceutical represents a key milestone in the implementation of Huajian's ETHK blockchain financial ecosystem strategy and the innovative "ETHK global RWA exchange" business model [1] - This partnership is intended to create a replicable model that validates the feasibility and potential of the innovative approach [1] Group 2: Commitment to Economic Development - Huajian Medical emphasizes that the ultimate mission of financial technology is to serve the real economy and create inclusive value, which this collaboration exemplifies [2] - The company aims to leverage technology to assist classic national brands like Renhe Pharmaceutical in their digital transformation, promoting successful ecological models across various industries [2] Group 3: Future Growth and Synergy - The board believes that this collaboration will generate significant synergies, positively impacting the strategic transformation and value reassessment of both companies [2] - Huajian Medical plans to work closely with Renhe Pharmaceutical to ensure the successful launch and stable operation of the world's first OTC RWA exchange, aiming for high standards and quality [2]

Group 1 - The Hang Seng Index rose by 0.07%, gaining 19 points to close at 26,465 points, while the Hang Seng Tech Index increased by 0.39% [1] - The early trading volume in Hong Kong stocks reached 160.2 billion HKD [1] Group 2 - New pharmaceutical stocks in the Hong Kong Stock Connect saw significant gains, with ZhiJie AnKang-B (02617) surging over 49%, reaching a market capitalization of over 240 billion HKD; BaiZe Medical (02609) rose over 76%; and TongYuanKang Pharmaceutical-B (02410) increased by over 36% [1] - Fosen Pharmaceutical (01652) experienced a dramatic rise of over 410%, closing at 1.35 HKD, up 297%, following the approval of Metformin and Ertugliflozin tablets [2] - Shanghai Fudan (01385) increased by 5.87%, with the company well-prepared for supply chain disruptions, and Morgan Stanley noted limited impact on demand [2] - SF Express (09699) rose over 6% as its "SoFast" service officially launched in Macau, with Daiwa optimistic about the company's revenue growth prospects [2] - Valiant Bio-B (09887) increased by over 13%, with its core product LBL-024 for melanoma completing its first patient dosing in trials [2] - Bilibili-W (09626) rose by 2.78%, accumulating a total increase of about 25% over the past six days, with the new game "Three Kingdoms: Hundred Generals" set for testing in October [2] - LionTeng Holdings (02562) surged over 7% as it plans to acquire leading companies in artificial intelligence and blockchain to expand its digital finance layout [2] - GCL-Poly Energy (03800) rose by 3.97%, planning a discounted placement to raise approximately 5.392 billion HKD for structural adjustments in polysilicon capacity [2] - China General Nuclear Power Corporation Mining (01164) increased by 6.7%, as the U.S. seeks to expand its strategic uranium reserves, with institutions expecting a recovery in uranium prices [2] - Yunfeng Financial (00376) fell over 16% after announcing a discounted placement to raise about 1.15 billion HKD [2]

Market Overview - The Hang Seng Index rose by 0.07%, gaining 19 points to close at 26,465 points, while the Hang Seng Tech Index increased by 0.39% [1] - Early trading volume in Hong Kong stocks reached HKD 160.2 billion [1] Notable Stock Movements - New pharmaceutical stocks in the Hong Kong Stock Connect surged, with Yaojie Ankang-B (02617) rising over 49%, reaching a market capitalization of over HKD 240 billion [1] - Baize Medical (02609) saw an increase of over 76% [1] - Tongyuan Kang Pharmaceutical-B (02410) rose by over 36% [1] Specific Company Highlights - Fosen Pharmaceutical (01652) experienced a dramatic rise of over 410%, closing at HKD 1.35, up 297%, following the approval of Metformin and Ertugliflozin tablets [2] - Shanghai Fudan (01385) increased by 5.87%, with the company prepared for supply chain disruptions, and Morgan Stanley noted limited impact on demand [2] - SF Express (09699) rose by over 6% as its "SoFast" service launched in Macau, with positive revenue growth prospects according to Daiwa [2] - Valiant Pharmaceuticals-B (09887) increased by over 13%, completing the first medication trial for its core product LBL-024 for melanoma [2] - Bilibili-W (09626) rose by 2.78%, accumulating a 25% increase over six days, with the new game "Three Kingdoms: Hundred Generals" set for testing in October [2] - Liontech Holdings (02562) surged over 7% as it plans to acquire a leading AI and blockchain company to expand its digital finance footprint [2] - GCL-Poly Energy (03800) rose by 3.97%, planning a discounted share placement to raise approximately HKD 5.392 billion for structural adjustments in polysilicon capacity [2] - CGN Mining (01164) increased by 6.7% amid expectations of rising uranium prices as the U.S. seeks to expand its strategic uranium reserves [2] - Yunfeng Financial (00376) fell over 16% after announcing a discounted share placement to raise about HKD 1.15 billion [2]

Core Viewpoint - The article highlights significant movements in the Hong Kong and US stock markets, focusing on specific companies and their recent performance, driven by various strategic announcements and market conditions. Hong Kong Stock Market Summary - China General Nuclear Power Corporation (01164) rose over 6% following US Energy Secretary Chris Wright's suggestion to consider expanding strategic uranium reserves, indicating potential upward price adjustments for uranium [1] - Yunfeng Financial (00376) fell over 18% after announcing a rights issue at a discount of approximately 16.8%, aiming to raise about HKD 1.15 billion [1] - GCL-Poly Energy Holdings (03800) increased over 2% as it plans a rights issue at a discount of about 8.73%, targeting net proceeds of HKD 5.392 billion for structural adjustments in polysilicon production [1] - Lion Group Holding (02562) surged over 6% after signing a letter of intent to acquire a leading AI and blockchain company, expanding its digital finance footprint [1] - Pharmaron Beijing Co., Ltd. (02617) skyrocketed over 53% after being included in the Hong Kong Stock Connect list, with a cumulative increase of nearly 10 times since its inclusion, and northbound investors adding over HKD 300 million in two days [1] - Anta Sports Products (02020) rose over 2% as retail sales of sports goods showed rapid growth in the first eight months, indicating marginal improvement in sales [1] - SF Technology (09699) increased over 5% after launching its "SoFast" brand in Macau, marking a significant step in its overseas business expansion [1] - Shanghai Fudan (01385) rose over 6% as Morgan Stanley reported the company is well-prepared for supply chain disruptions, with limited demand impact expected [2] - Tianyue Advanced (02631) increased over 1% after being included in the Hong Kong Stock Connect, with silicon carbide expected to see new market growth [2] - Valiant Co., Ltd. (09887) rose over 10% after announcing the completion of the first patient dosing in a trial for its core product LBL-024 for melanoma [2] US Stock Market Summary - Tesla (TSLA.US) rose 3.56% as the head of its German factory announced an increase in production plans for Q3 and Q4 due to strong sales data [3] - NVIDIA (NVDA.US) fell 0.04% as it faces further investigation for violating antitrust laws [3] - Hesai Technology (HSAI.US) increased 4.31% after announcing a partnership with a leading US Robotaxi company, securing over USD 40 million in lidar orders [3] - XPeng Motors (XPEV.US) rose 2.20% after formalizing a deep cooperation with Magna Steyr in Austria, marking the start of local production in Europe [3] - NIO (NIO.US) increased 4.34% as it announced the NIO Day 2025 event, scheduled for September 20, where the new ES8 will be launched [3] - Apple (AAPL.US) rose 1.12% as Morgan Stanley reported that demand for the iPhone 17 series exceeded that of the previous year's iPhone 16 series during its first week of launch [4] - Fangdd Network Group (DUO.US) fell 9.17% following the National Bureau of Statistics' report indicating a decline in residential property prices in August [3] - Alibaba (BABA.US) rose 1.92% ahead of the 2025 Cloud Summit scheduled for September 24-26 in Hangzhou [4] - ASML Holding (ASML.US) increased 6.56% after announcing a EUR 1.3 billion investment in French AI startup Mistral AI, becoming its largest shareholder [4] - Bilibili (BILI.US) rose 6.40% as it announced the upcoming public test of its new strategy card game, "Three Kingdoms: Hundred Generals Card" [4] - Oracle (ORCL.US) increased 3.41% as management disclosed that its cloud infrastructure revenue is set to experience steep growth [4]

Economic Performance - Shanghai's GDP reached 5.4 trillion yuan in 2024, with a year-on-year growth of 5.0%[2] - Fixed asset investment grew by 4.8%, with industrial investment showing a strong increase of 11.1%[3] - Total retail sales of consumer goods decreased by 3.1% year-on-year, amounting to 17,940 billion yuan[3] Trade and Employment - The total import and export volume reached 4.3 trillion yuan, a year-on-year increase of 1.3%[3] - The urban unemployment rate averaged 4.2%, down by 0.3 percentage points from the previous year[3] - Per capita disposable income in Shanghai increased by 4.2%, reaching 88,366 yuan[43] Financial Sector Development - The balance of deposits and loans reached 22.0 trillion yuan and 12.3 trillion yuan respectively, with year-on-year growth of 7.7% and 9.8%[4] - New loans for small and micro enterprises had a weighted average interest rate of 3.25%, down by 0.37 percentage points year-on-year[5] - The social financing scale increased by 10,612 billion yuan, exceeding the previous year by 3,201 billion yuan[5] Industrial Growth - The total industrial output value was 39 trillion yuan, with a year-on-year growth of 0.7%[3] - The added value of strategic emerging industries reached 17,201 billion yuan, growing by 1.8%[3] - The three leading industries (integrated circuits, biomedicine, and artificial intelligence) achieved a combined output value of 4,618 billion yuan, with a growth rate of 10.8%[3]